WILMINGTON, Del., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Cleveland BioLabs, Inc. (“Cleveland”) (NASDAQ GS: CBLI) regarding possible breaches of fiduciary duties and other violations of law related to Cleveland’s agreement to merge with Cytocom, Inc. (“Cytocom”). Under the terms of the agreement, Cleveland will issue a number of shares of Cleveland common stock to shareholders of Cytocom.
To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-cleveland-biolabs-inc.
You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or firstname.lastname@example.org.
Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.
Attorney advertising. Prior results do not guarantee a similar outcome.